Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17- demethoxygeldanamycin, and rapamycin

Journal of Controlled Release

Volumn 163, Issue 1, 2012, Pages 93-99

  Shin, Ho Chul ^a,c   Cho, Hyunah ^a   Lai, Tsz Chung ^a   Kozak, Kevin R ^b   Kolesar, Jill M ^a   Kwon, Glen S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c SK Chemicals   (South Korea)

Author keywords

17 Allylamino 17 demethoxygeldanamycin (17 AAG); Paclitaxel; PEG b PLA micelles; Pharmacokinetics; Rapamycin

Indexed keywords

17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN (17-AAG); ANTICANCER DRUG; CONCENTRATION-TIME; D ,L-LACTIC ACID; DRUG FORMULATIONS; HIGH DOSE; PACLITAXEL; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC PROFILES; PHARMACOKINETIC STUDIES; POLYMERIC MICELLE; RAPAMYCIN;

LACTIC ACID; MAMMALS; MICELLES; ORGANIC SOLVENTS; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; SURFACE ACTIVE AGENTS;

DRUG DOSAGE;

MACROGOL; PACLITAXEL; POLYLACTIC ACID; RAPAMYCIN; TANESPIMYCIN;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; FEMALE; MEAN RESIDENCE TIME; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMBINATIONS; FEMALE; LACTAMS, MACROCYCLIC; LACTATES; MICE; MICELLES; PACLITAXEL; POLYETHYLENE GLYCOLS; SIROLIMUS;

EID: 84866732669     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.04.024     Document Type: Conference Paper

References (22)

1. S. Grant Cotargeting survival signaling pathways in cancer J. Clin. Invest. 118 2008 3003 3006
2. M.M. Roforth, and C. Tan Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells Anticancer Drugs 19 2008 681 688
3. D.M. Nguyen, D. Lorang, G.A. Chen, J.H.T. Stewart, E. Tabibi, and D.S. Schrump Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis Ann. Thorac. Surg. 72 2001 371 378 (discussion 378-379)
4. A. Sawai, S. Chandarlapaty, H. Greulich, M. Gonen, Q. Ye, C.L. Arteaga, W. Sellers, N. Rosen, and D.B. Solit Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel Cancer Res. 68 2008 589 596
5. N. Sain, B. Krishnan, M.G. Ormerod, A. De Rienzo, W.M. Liu, S.B. Kaye, P. Workman, and A.L. Jackman Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol. Cancer Ther. 5 2006 1197 1208
6. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 42 2003 665 685
7. D.B. Solit, A.D. Basso, A.B. Olshen, H.I. Scher, and N. Rosen Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol Cancer Res. 63 2003 2139 2144
8. H.C. Shin, A.W.G. Alani, H. Cho, Y. Bae, J.M. Kolesar, and G.S. Kwon A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol. Pharm. 8 2011 1257 1265
9. S.C. Kim, D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S.W. Kim, and M.H. Seo In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Control. Release 72 2001 192 202
10. J.R. Hasenstein, H.C. Shin, K. Kasmerchak, D. Buehler, G.S. Kwon, and K.R. Kozak Anti-tumor activity of triolimus: a novel multi-drug loaded micelle containing paclitaxel, rapamycin and 17-AAG 2011
11. Guidance for Industry Bioanalytical Method Validation 2001 FDA. U.S. Department of Health and Human Services, Center of Drug Evaluation and Research, and Center for Veterinary Medicine 25
12. S.C. Kim, J. Yu, J.W. Lee, E.S. Park, and S.C. Chi Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution J. Pharm. Biomed. Anal. 39 2005 170 176
13. M.P. Xiong, J.A. Yanez, G.S. Kwon, N.M. Davies, and M.L. Forrest A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats J. Pharm. Sci. 98 2009 1577 1586
14. J.A. Yanez, M.L. Forrest, Y. Ohgami, G.S. Kwon, and N.M. Davies Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon- caprolactone) micelles of rapamycin Cancer Chemother. Pharmacol. 61 2008 133 144
15. M.J. Egorin, D.M. Rosen, J.H. Wolff, P.S. Callery, S.M. Musser, and J.L. Eiseman Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations Cancer Res. 58 1998 2385 2396
16. A. Sparreboom, O. van Tellingen, W.J. Nooijen, and J.H. Beijnen Tissue distribution, metabolism and excretion of paclitaxel in mice Anticancer Drugs 7 1996 78 86
17. Center for drug evaluation and research application number: 021083, pharmacological reviews 1999 FDA. U.S. Department of Health and Human Services, Center of Drug Evaluation and Reserach, and Center for Veterinary Medicine
18. Investigator's brochure for 17-Allylaminogeldanamycin (17-AAG) 2004 National. Cancer. Institute
19. M. Campone, V. Levy, E. Bourbouloux, D. Berton Rigaud, D. Bootle, C. Dutreix, U. Zoellner, N. Shand, F. Calvo, and E. Raymond Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours Br. J. Cancer 100 2009 315 321
20. H.C. Shin, A.W. Alani, D.A. Rao, N.C. Rockich, and G.S. Kwon Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs J. Control. Release 140 2009 294 300
21. L.D. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E.C. Ramsay, M.B. Bally, and A.S. Janoff Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 5 2006 1854 1863
22. L.D. Mayer, and A.S. Janoff Optimizing combination chemotherapy by controlling drug ratios Mol. Interv. 7 2007 216 223